Clinical Trials Browser

OTHER × trebananib × Genitourinary × Clear all

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT01907308 2014-04-29

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell